The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [2][3]. Group 1: Company Developments - The class period for the lawsuit is from July 30, 2024, to January 8, 2025, during which shareholders are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [2][3]. - Intellia's management had previously expressed confidence in the timeline for the NTLA-3001 study, expecting to dose the first patient in the second half of 2024 [2]. - On January 9, 2025, Intellia announced the halting of all NTLA-3001 research and a workforce reduction of 27% in 2025, indicating a shift in focus to other pharmaceutical developments [2]. Group 2: Financial Impact - Following the announcement of the discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to$10.20 per share on January 10, 2025 [2]. Group 3: Legal Proceedings - Shareholders have until April 14, 2025, to register for the class action lawsuit, with no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4].